Search results
Found 113 matches for
EMPA-KIDNEY is a clinical trial testing whether taking a single pill of empagliflozin every day prevents worsening of kidney disease or deaths from heart disease in people who have chronic kidney disease.
ASN2024 Long-term Effects of Empagliflozin in Chronic Kidney Disease (25-Oct-2024)
Presented at the American Society of Nephrology: Kidney Week 2024 (San Diego)
ASN2024 EMPA-KIDNEY Health Economic abstract (25-Oct-2024)
Presented at the American Society of Nephrology: Kidney Week 2024 (San Diego)
Renal outcome meta-analysis protocol: large empaglifozin trials (03-Oct-2024)
Effects of empagliflozin versus placebo on kidney outcomes: Protocol and outline analysis plan for an individual participant-level data renal meta-analysis
2024-10-03_Protocol_for_IPD_meta-analysis_of_Empagliflozin_trials.pdf (637 KB)
Protocol Supplement: EMPA-KIDNEY Post-Trial Follow-up v1.1
EMPA-KIDNEY PTFU Protocol Supplement v1.1 12-Nov-2021. Uploaded 03-Sep-2024.
EMPA-KIDNEY試験担当者用 個人情報の取り扱いについて（日本語訳）(Japanese v1.3, 10-May-2023)
EMPA-KIDNEY Privacy Notice for trial staff (Japanese).
致EMPA-KIDNEY研究人员隐私声明（中文版) (Chinese, v1.3, 10-May-2023)
EMPA-KIDNEY Privacy Notice for trial staff (Chinese)
慢性腎臓病患者にみるエンパグリフロジンの効果における腎臓病の原疾患のインパクト : EMPA-KIDNEY試験の二次解析
Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY trial 2023-10-24 [投稿論文のアブストラクト日本語訳 (Japanese Translation)]
原发性肾脏疾病对恩格列净在慢性肾脏疾病患者中的疗效的影响： EMPA-KIDNEY试验的次要分析
Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY trial [已发表文章摘要部分的中文翻译 (Chinese translation)]
Secondary Analysis of the EMPA-KIDNEY Trial - Publication Supplementary Materials (04-Dec-2023)
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial - Supplementary Materials Published in Lancet Diabetes Endocrinol
SecondaryAnalysisEMPA-KIDNEY_Supplement_2023-12-04.pdf (853 KB)
Secondary analyses of the EMPA-KIDNEY trial - Results Publication (04-Dec-2023)
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Published in Lancet Diabetes Endocrinal 04-Dec-2023
SecondaryAnalysisEMPA-KIDNEY_Publication_2023-12-04.pdf (596 KB)
EMPA-KIDNEY MRI Substudy results (17-Jun-2023)
Presentation by Parminder Judge at the European Renal Association on the "Effects of Empagliflozin on Renal and Cardiac MRI Measures in Patients with Chronic Kidney Disease".
EMPA-KIDNEY Bioimpedance Substudy results (17-Jun-2023)
Presentation by Kaitlin Mayne (17-Jun-2023) at the European Renal Association on the “Effects of Empagliflozin on Fluid Overload in Chronic Kidney Disease: an EMPA-KIDNEY Bioimpedance Substudy.
EMPA-KIDNEY_ERA_Bioimpedance_Substudy_results_17-Jun-2023.pdf (3 MB)
EMPA-KIDNEY Presentation for Patient Results Meetings
Slideset for patient results meeting
EMPA-KIDNEY 参加者ニュースレター 2022年11月4日（日本語）
Newsletter (Japanese) for EMPA-KIDNEY participants
Japanese translation EMPA-KIDNEY Participant Newsletter v1.0 2022-Nov-04.pdf (1 MB)